GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to a Diagnostic Assay for Non-Alcoholic SteatoHepatitis

January 3, 2019

Applied Clinical Trials

LabCorp, a global life sciences company, and GENFIT, a late-stage biopharmaceutical company, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp’s drug development business. The agreement hopes to expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.

Read the full release here.

Related Content:

News